Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431

Etan Orgel; Kristin R. Knight; Doojduen Villaluna; Mark Krailo; Adam J. Esbenshade; Lillian Sung; David R. Freyer

doi:10.1002/pbc.30550

Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431

Etan Orgel, Kristin R. Knight, Doojduen Villaluna, Mark Krailo, Adam J. Esbenshade, Lillian Sung, David R. Freyer

Audiology

Research output: Contribution to journal › Article › peer-review

Abstract

In two randomized trials (Children's Oncology Group ACCL0431 and International Childhood Liver Tumour Strategy Group SIOPEL-6), sodium thiosulfate (STS) demonstrated efficacy in preventing cisplatin-induced hearing loss (CIHL). However, the measures used in those trials have been superseded by the consensus International Society of Paediatric Oncology (SIOP) Ototoxicity Scale. To provide benchmark data for STS efficacy when using this contemporary scale, we reanalyzed ACCL0431 hearing outcomes with the SIOP scale and using multiple timepoints. Compared to the control arm, STS significantly reduced CIHL when assessed by the SIOP scale across these different approaches. These results provide critical data to inform treatment discussions and support future potential trial designs comparing otoprotectants.

Original language	English (US)
Article number	e30550
Journal	Pediatric Blood and Cancer
Volume	70
Issue number	9
DOIs	https://doi.org/10.1002/pbc.30550
State	Published - Sep 2023

Keywords

childhood cancer
cisplatin
hearing loss
ototoxicity
sodium thiosulfate

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.30550

Cite this

Orgel, E., Knight, K. R., Villaluna, D., Krailo, M., Esbenshade, A. J., Sung, L., & Freyer, D. R. (2023). Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431. Pediatric Blood and Cancer, 70(9), Article e30550. https://doi.org/10.1002/pbc.30550

Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431. / Orgel, Etan; Knight, Kristin R.; Villaluna, Doojduen et al.
In: Pediatric Blood and Cancer, Vol. 70, No. 9, e30550, 09.2023.

Research output: Contribution to journal › Article › peer-review

Orgel, E, Knight, KR, Villaluna, D, Krailo, M, Esbenshade, AJ, Sung, L & Freyer, DR 2023, 'Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431', Pediatric Blood and Cancer, vol. 70, no. 9, e30550. https://doi.org/10.1002/pbc.30550

@article{f7e2e13b414b478a93240ba48296c559,

title = "Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431",

abstract = "In two randomized trials (Children's Oncology Group ACCL0431 and International Childhood Liver Tumour Strategy Group SIOPEL-6), sodium thiosulfate (STS) demonstrated efficacy in preventing cisplatin-induced hearing loss (CIHL). However, the measures used in those trials have been superseded by the consensus International Society of Paediatric Oncology (SIOP) Ototoxicity Scale. To provide benchmark data for STS efficacy when using this contemporary scale, we reanalyzed ACCL0431 hearing outcomes with the SIOP scale and using multiple timepoints. Compared to the control arm, STS significantly reduced CIHL when assessed by the SIOP scale across these different approaches. These results provide critical data to inform treatment discussions and support future potential trial designs comparing otoprotectants.",

keywords = "childhood cancer, cisplatin, hearing loss, ototoxicity, sodium thiosulfate",

author = "Etan Orgel and Knight, {Kristin R.} and Doojduen Villaluna and Mark Krailo and Esbenshade, {Adam J.} and Lillian Sung and Freyer, {David R.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.",

year = "2023",

month = sep,

doi = "10.1002/pbc.30550",

language = "English (US)",

volume = "70",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "9",

}

TY - JOUR

T1 - Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale

T2 - A report from the Children's Oncology Group study ACCL0431

AU - Orgel, Etan

AU - Knight, Kristin R.

AU - Villaluna, Doojduen

AU - Krailo, Mark

AU - Esbenshade, Adam J.

AU - Sung, Lillian

AU - Freyer, David R.

PY - 2023/9

Y1 - 2023/9

N2 - In two randomized trials (Children's Oncology Group ACCL0431 and International Childhood Liver Tumour Strategy Group SIOPEL-6), sodium thiosulfate (STS) demonstrated efficacy in preventing cisplatin-induced hearing loss (CIHL). However, the measures used in those trials have been superseded by the consensus International Society of Paediatric Oncology (SIOP) Ototoxicity Scale. To provide benchmark data for STS efficacy when using this contemporary scale, we reanalyzed ACCL0431 hearing outcomes with the SIOP scale and using multiple timepoints. Compared to the control arm, STS significantly reduced CIHL when assessed by the SIOP scale across these different approaches. These results provide critical data to inform treatment discussions and support future potential trial designs comparing otoprotectants.

AB - In two randomized trials (Children's Oncology Group ACCL0431 and International Childhood Liver Tumour Strategy Group SIOPEL-6), sodium thiosulfate (STS) demonstrated efficacy in preventing cisplatin-induced hearing loss (CIHL). However, the measures used in those trials have been superseded by the consensus International Society of Paediatric Oncology (SIOP) Ototoxicity Scale. To provide benchmark data for STS efficacy when using this contemporary scale, we reanalyzed ACCL0431 hearing outcomes with the SIOP scale and using multiple timepoints. Compared to the control arm, STS significantly reduced CIHL when assessed by the SIOP scale across these different approaches. These results provide critical data to inform treatment discussions and support future potential trial designs comparing otoprotectants.

KW - childhood cancer

KW - cisplatin

KW - hearing loss

KW - ototoxicity

KW - sodium thiosulfate

UR - http://www.scopus.com/inward/record.url?scp=85164531097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164531097&partnerID=8YFLogxK

U2 - 10.1002/pbc.30550

DO - 10.1002/pbc.30550

M3 - Article

C2 - 37416942

AN - SCOPUS:85164531097

SN - 1545-5009

VL - 70

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 9

M1 - e30550

ER -

Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this